Navigation Links
Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComm's CRO Preferred Program
Date:8/18/2009

FORT LAUDERDALE, Fla., Aug. 18 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that it has been selected by Amarex, a Mid-Atlantic based Contract Research Organization (CRO) to provide eClinical solutions for an upcoming Phase III trial investigating the use of a medical device for wound healing. The study will be conducted at over 30 sites and will recruit up to 300 patients over the course of two years. Amarex also joins OmniComm's CRO Preferred Program, which will allow them to offer OmniComm's flexible, robust electronic data capture solution, TrialMaster(TM), to their clients. Amarex also benefits from the CRO Program's distinct advantages that include fixed pricing with no hidden fees, complete sales and marketing support, and dedicated hosting services in OmniComm's world class hosting facility.

"We are honored that such a well-reputed CRO like Amarex has joined our CRO Preferred Program and look forward to working closely with them on this high profile study," remarked Stephen Johnson, COO of OmniComm Systems. "Amarex has a reputation for delivering superior service to their customers - a commitment that we share here at OmniComm. The combination of our products and services will be beneficial for both companies, but more importantly will offer our customers the solutions they need to bring life saving drugs and devices to market."

About Amarex Clinical Research

Amarex Clinical Research, Inc. is a global clinical research organization supplying a full range of clinical trial services to the pharmaceutical, biotech, and medical device communities. Amarex has managed studies in a breadth of therapeutic areas in Phase I through Phase IV study development. The company employs approximately 50 personnel in its offices located in the United States, and reaches clients worldwide through its Internet-based data collection and reporting capabilities. Amarex is headquartered in Germantown, MD. For more information, please visit the company's Web site at http://www.amarexcro.com.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    CONTACT:
    Catherine Lemercier              Gary Nash
    OmniComm Systems, Inc.           CEOcast, Inc. for OmniComm
    954-473-1254 Extension 283       212-732-4300
    clemercier@omnicomm.com          gnash@ceocast.com

    Stephen Johnson
    954-377-1726


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
3. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
4. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
5. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
6. Radius Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
7. Project Zero Delay Accelerates Drugs Path to Clinical Trial
8. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
9. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
10. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
11. R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
Breaking Medicine News(10 mins):